Retrieve available abstracts of 111 articles: HTML format
Single Articles
June 2025
NOSAKA K, Fukushima T JSH practical guidelines for hematological malignancies, 2023: II. lymphoma
9-adult T-cell leukemia-lymphoma (ATL).
Int J Hematol. 2025 Jun 4. doi: 10.1007/s12185-025-04011. PubMed
MASUDA Y, Sadato D, Toya T, Hosoda Y, et al Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation
center experience of 63 patients.
Int J Hematol. 2025;121:820-832. PubMedAbstract available
May 2025
TAKAHASHI N, Kikushige Y, Nakamae H, Goto T, et al Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from
the Japanese subgroup of ASC4FIRST.
Int J Hematol. 2025 May 26. doi: 10.1007/s12185-025-04014. PubMedAbstract available
KONISHI H, Tachibana T, Arai S, Izumi A, et al Comparison of clinical outcomes between preemptive and maintenance therapy after
allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Int J Hematol. 2025 May 23. doi: 10.1007/s12185-025-04009. PubMedAbstract available
IKEDA J, Shiba N, Kato S, Kunimoto H, et al Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with
genetic and metabolic vulnerabilities.
Int J Hematol. 2025;121:694-705. PubMedAbstract available
SAKURAI Y, Yanagimachi M, Ito M, Hirose A, et al A case of acute promyelocytic leukemia complicated by mitochondrial disease.
Int J Hematol. 2025 May 1. doi: 10.1007/s12185-025-03992. PubMedAbstract available
April 2025
OKA S, Akagi Y, Mituyoshi T, Ono K, et al Successful treatment of myeloid blast phase chronic myelogenous leukemia with the
JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon
alfa-2b in an elderly patient.
Int J Hematol. 2025 Apr 29. doi: 10.1007/s12185-025-03994. PubMedAbstract available
ITO T, Kamimura T, Kiguchi T, Kato K, et al Correction: Venetoclax treatment for chronic lymphocytic leukemia/small
lymphocytic leukemia in Japan: post-marketing surveillance.
Int J Hematol. 2025 Apr 11. doi: 10.1007/s12185-025-03978. PubMed
NGUYEN T, Harama D, Tamai M, Kagami K, et al Synergistic effect of asciminib with reduced doses of ponatinib in human Ph
+ myeloid leukemia with the T315M mutation.
Int J Hematol. 2025 Apr 10. doi: 10.1007/s12185-025-03981. PubMedAbstract available
IZUTSU K, Ishikawa T, Shimada K, Kubo K, et al Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with
Waldenstrom macroglobulinemia and CLL/SLL.
Int J Hematol. 2025;121:483-493. PubMedAbstract available
TOKUSHIGE J, Taoka K, Nishikawa M, Jona M, et al Discovery of a second, distinct development pattern of leukemic conversion from
paroxysmal nocturnal hemoglobinuria.
Int J Hematol. 2025;121:543-546. PubMedAbstract available
NISHIWAKI S, Terakura S, Morishita T, Goto T, et al Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.
Int J Hematol. 2025;121:494-503. PubMedAbstract available
March 2025
KOH K, Kosaka Y, Okamoto Y, Maeda N, et al Phase 2 multicenter study of pegaspargase in Japanese patients with previously
untreated acute lymphoblastic leukemia.
Int J Hematol. 2025 Mar 31. doi: 10.1007/s12185-025-03976. PubMedAbstract available
NISHIMURA A, Tamura A, Fujikawa T, Inoue S, et al KMT2A-CBL fusion gene in the first reported case of T-cell acute lymphoblastic
leukemia associated with Wiedemann-Steiner syndrome.
Int J Hematol. 2025 Mar 28. doi: 10.1007/s12185-025-03975. PubMedAbstract available
YOSHIKAWA T, Ishida H, Watanabe A, Yuza Y, et al Favorable outcomes of de novo advanced phases of pediatric chronic myeloid
leukemia in the tyrosine kinase inhibitor era.
Int J Hematol. 2025 Mar 15. doi: 10.1007/s12185-025-03953. PubMedAbstract available
KAMIUNTEN A, Kameda T, Sekine M, Kawano H, et al Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice.
Int J Hematol. 2025 Mar 11. doi: 10.1007/s12185-025-03963. PubMedAbstract available
TAKAMATSU Y JSH practical guidelines for hematological malignancies, 2023: leukemia-5.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Int J Hematol. 2025 Mar 1. doi: 10.1007/s12185-025-03914. PubMed
February 2025
ABUMIYA M, Saito A, Fujioka Y, Miura M, et al Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in
patients with chronic myeloid leukemia.
Int J Hematol. 2025 Feb 25. doi: 10.1007/s12185-025-03954. PubMedAbstract available
ISHII S, Arakawa Y, Ishii H, Yokoyama K, et al A novel stroma-dependent leukemia cell line from a patient with mixed-phenotype
acute leukemia with Ph chromosome and PAX5 mutation.
Int J Hematol. 2025 Feb 20. doi: 10.1007/s12185-025-03944. PubMedAbstract available
MATSUMOTO Y, Kato D, Muramatsu A, Sugitani M, et al Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with
TP53 mutations.
Int J Hematol. 2025 Feb 19. doi: 10.1007/s12185-025-03938. PubMedAbstract available
January 2025
FENG LS, Li HY, Tang A, Xu ML, et al Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and
aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic
leukemia.
Int J Hematol. 2025 Jan 23. doi: 10.1007/s12185-025-03915. PubMedAbstract available
MIYAZAKI Y JSH practical guidelines for hematological malignancies, 2023: leukemia-6.
Myelodysplastic syndromes (MDS).
Int J Hematol. 2025 Jan 14. doi: 10.1007/s12185-024-03906. PubMed
MIYAZAKI T, Uno S, Fujimori H, Motegi Y, et al Safety and effectiveness of lenalidomide in Japanese patients with
relapsed/refractory ATLL: post-marketing surveillance.
Int J Hematol. 2025;121:79-88. PubMedAbstract available
SAWA M, Miyamoto T, Kim HJ, Hiramatsu Y, et al A phase 1/2 study of gilteritinib in combination with chemotherapy in newly
diagnosed patients with AML in Asia.
Int J Hematol. 2025;121:56-67. PubMedAbstract available
December 2024
CHIRIAC R Pseudo-Chediak-Higashi inclusions and Auer rods in a case of therapy-related
acute monocytic leukemia.
Int J Hematol. 2024 Dec 30. doi: 10.1007/s12185-024-03910. PubMed
UTSUNOMIYA A, Yasunaga JI, Tabuchi T, Nakano N, et al A 25-year clonal resurrection in adult T-cell leukemia-lymphoma relapse.
Int J Hematol. 2024 Dec 25. doi: 10.1007/s12185-024-03901. PubMedAbstract available
FUJITA H Correction: JSH practical guidelines for hematological malignancies, 2023:
leukemia-2-acute promyelocytic leukemia (APL).
Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03908. PubMed
MAEDA Y Correction: JSH practical guidelines for hematological malignancies, 2023: I.
Leukemia-1. Acute myeloid leukemia (AML).
Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03907. PubMed
ARAI H, Hosono N, Chi S, Fukushima K, et al A practice-oriented genome-profiling study for acute myeloid leukemia using the
novel HANDLE system: HM-screen-JAPAN02.
Int J Hematol. 2024 Dec 16. doi: 10.1007/s12185-024-03895. PubMedAbstract available
KOHSO A, Toyoda H, Hanaki R, Niwa K, et al Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and
relapsed acute lymphoblastic leukemia.
Int J Hematol. 2024 Dec 9. doi: 10.1007/s12185-024-03890. PubMedAbstract available
INAMURA J, Taketani T, Mochida M, Goto T, et al Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review
of the relevant literature.
Int J Hematol. 2024 Dec 4. doi: 10.1007/s12185-024-03881. PubMedAbstract available
SHIMONODAN H, Sakaguchi K, Ishihara T, Okamoto Y, et al Silent inactivation of asparaginase in Japan: results of the prospective
ALL-ASP19 trial.
Int J Hematol. 2024;120:725-734. PubMedAbstract available
November 2024
TAKAHASHI N, Takenaka K, Iriyama N, Kirito K, et al JSH practical guidelines for hematological malignancies, 2023: leukemia-4.
Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03865. PubMed
MUTA T, Masamoto Y, Yamamoto G, Kurahashi S, et al Real-world effectiveness and safety of ibrutinib in patients with chronic
lymphocytic leukemia in Japan: the Orbit study.
Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03875. PubMedAbstract available
SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell
leukemia/lymphoma.
Int J Hematol. 2024 Nov 25. doi: 10.1007/s12185-024-03880. PubMedAbstract available
ISHII Y, Fujisawa S, Miyazaki T, Nakajima Y, et al Real-world toxicity and efficacy of asciminib in heavily pretreated patients with
chronic myeloid leukemia.
Int J Hematol. 2024 Nov 19. doi: 10.1007/s12185-024-03873. PubMedAbstract available
SABURI M, Nishikawa T, Kawano K, Ohtsuka E, et al Successful complete remission after induction therapy with CPX-351 for acute
myeloid leukemia with myelodysplasia-related changes accompanied by double-minute
chromosomes and MYC gene amplification.
Int J Hematol. 2024 Nov 11. doi: 10.1007/s12185-024-03876. PubMed
NAKA R, Shimomura Y, Miura M, Nagai Y, et al Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on
hemodialysis.
Int J Hematol. 2024 Nov 7. doi: 10.1007/s12185-024-03869. PubMedAbstract available
ISHIKAWA Y Recent progress in AML with recurrent genetic abnormalities.
Int J Hematol. 2024;120:525-527. PubMedAbstract available
SUGIURA H, Ishikawa T, Kuroi T, Okamoto S, et al Comparison of disease and risk classifications of AML before and after
incorporation of NGS analysis of bone marrow samples.
Int J Hematol. 2024;120:594-600. PubMedAbstract available
ISHIKAWA Y, Ushijima Y, Kiyoi H Recent advances in AML with mutated NPM1.
Int J Hematol. 2024;120:556-565. PubMedAbstract available
KENNEDY VE, Smith CC FLT3 targeting in the modern era: from clonal selection to combination therapies.
Int J Hematol. 2024;120:528-540. PubMedAbstract available
October 2024
OUCHI F, Shingai N, Najima Y, Sadato D, et al Quizartinib with donor lymphocyte infusion for post-transplant relapse of
FLT3-ITD-positive acute myeloid leukemia.
Int J Hematol. 2024 Oct 26. doi: 10.1007/s12185-024-03863. PubMedAbstract available
HASHIMOTO M, Kato T, Yokota K, Sakamoto H, et al Improved survival among elderly patients with aggressive adult T-cell
leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy.
Int J Hematol. 2024 Oct 10. doi: 10.1007/s12185-024-03857. PubMedAbstract available
CHIRIAC R Therapy-related acute myeloid leukemia with inv(16)(p13.1q22).
Int J Hematol. 2024 Oct 8. doi: 10.1007/s12185-024-03858. PubMed
URRUTIA S, Takahashi K Precision medicine in AML: overcoming resistance.
Int J Hematol. 2024;120:439-454. PubMedAbstract available
YOSHIMARU R, Minami Y Achievement of deep molecular response and treatment-free remission with
asciminib treatment in CML.
Int J Hematol. 2024;120:512-514. PubMedAbstract available
SAITO S, Nakazawa Y CAR-T cell therapy in AML: recent progress and future perspectives.
Int J Hematol. 2024;120:455-466. PubMedAbstract available
September 2024
KINOSHITA M, Saito Y, Otani K, Uehara Y, et al Mitochondrial dynamics as a potential therapeutic target in acute myeloid
leukemia.
Int J Hematol. 2024 Sep 16. doi: 10.1007/s12185-024-03843. PubMedAbstract available
HATTA Y, Izutsu K, Onizuka M, Dobashi N, et al JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute
lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL.
Int J Hematol. 2024 Sep 6. doi: 10.1007/s12185-024-03836. PubMed
YAMAGUCHI H Advances in pathogenesis research and challenges in treatment development for
acute myeloid leukemia.
Int J Hematol. 2024 Sep 3. doi: 10.1007/s12185-024-03837. PubMedAbstract available
MINAMI Y, Doki N, Matsuoka H, Yokota T, et al Asciminib in Patients With CML-CP Previously Treated With >/= 2 Tyrosine Kinase
Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL
Study.
Int J Hematol. 2024;120:305-313. PubMedAbstract available
SUZUKI K, Koyama D, Oka Y, Sato Y, et al Myeloid sarcoma with plasmacytoid dendritic cell-like proliferation associated
with IKZF1, ETV6 and DNMT3A mutations.
Int J Hematol. 2024;120:382-388. PubMedAbstract available
August 2024
NISHIJIMA M, Ido K, Okayama Y, Okamura H, et al A case of posttransplant isolated extramedullary relapse of acute lymphoblastic
leukemia achieving durable treatment-free remission with blinatumomab and donor
lymphocyte infusion.
Int J Hematol. 2024 Aug 30. doi: 10.1007/s12185-024-03839. PubMedAbstract available
GOTO H, Kada A, Ogawa C, Nishiuchi R, et al Treatment of relapsed acute lymphoblastic leukemia in children: an observational
study of the Japan Children's Cancer Group.
Int J Hematol. 2024 Aug 27. doi: 10.1007/s12185-024-03838. PubMedAbstract available
ITO T, Kamimura T, Kiguchi T, Kato K, et al Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia
in Japan: post-marketing surveillance.
Int J Hematol. 2024 Aug 21. doi: 10.1007/s12185-024-03832. PubMedAbstract available
NAGATA Y Molecular pathophysiology of germline mutations in acute myeloid leukemia.
Int J Hematol. 2024 Aug 16. doi: 10.1007/s12185-024-03824. PubMedAbstract available
URESHINO H, Takahashi N, Ikezoe T, Kameoka Y, et al A lower initial dose of bosutinib for patients with chronic myeloid leukemia
patients resistant and/or intolerant to prior therapy: a single-arm, multicenter,
phase 2 trial (BOGI trial).
Int J Hematol. 2024 Aug 13. doi: 10.1007/s12185-024-03830. PubMedAbstract available
OYA S, Ozawa H, Nakamura T, Mori A, et al CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab
ozogamicin-mediated cytotoxicity.
Int J Hematol. 2024;120:194-202. PubMedAbstract available
LU Y, Ma WB, Ren GM, Li YT, et al GPS2 promotes erythroid differentiation in K562 erythroleukemia cells primarily
via NCOR1.
Int J Hematol. 2024;120:157-166. PubMedAbstract available
ZHANG W, Li J, Yamamoto K, Goyama S, et al Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency.
Int J Hematol. 2024;120:186-193. PubMedAbstract available
July 2024
IKEDA S, Suzuki M, Tsunoda S, Ohta M, et al Dynamic changes in femoral bone marrow MRI in patients with chronic myelogenous
leukemia.
Int J Hematol. 2024 Jul 15. doi: 10.1007/s12185-024-03819. PubMed
KUROSAWA S, Nakazato T Immunohistochemical differentiation of extramedullary acute myeloid leukemia from
blastic plasmacytoid dendritic cell neoplasm.
Int J Hematol. 2024 Jul 10. doi: 10.1007/s12185-024-03817. PubMed
OYA S, Ozawa H, Morishige S, Maehiro Y, et al High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in
patients with favorable- or intermediate-risk acute myeloid leukemia.
Int J Hematol. 2024 Jul 4. doi: 10.1007/s12185-024-03814. PubMedAbstract available
SAJIKI D, Yoshida N, Muramatsu H, Sakaguchi K, et al Clinical features of immature leukemias in children.
Int J Hematol. 2024;120:117-127. PubMedAbstract available
May 2024
GONZALEZ-MANCERA MS, Lopategui J, Hoffman D, Kitahara S, et al B-cell prolymphocytic leukemia: an enduring bona fide entity.
Int J Hematol. 2024 May 26. doi: 10.1007/s12185-024-03774. PubMedAbstract available
ARAI S, Tachibana T, Izumi A, Takeda T, et al WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell
transplantation in patients with acute myeloid leukemia.
Int J Hematol. 2024 May 25. doi: 10.1007/s12185-024-03795. PubMedAbstract available
SHI X, Feng M, Nakada D Metabolic dependencies of acute myeloid leukemia stem cells.
Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03789. PubMedAbstract available
AKIYAMA H, Kantarjian H, Jabbour E, Issa G, et al Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03787. PubMedAbstract available
KAITO Y, Imai Y Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778. PubMedAbstract available
ITO M, Fukushima N Faggot cells observed in a patient with myelodysplastic syndrome with increased
blasts.
Int J Hematol. 2024;119:476-478. PubMed
April 2024
KATSUKI K, Tachibana T, Izumi A, Kim K, et al Acute mixed-lineage leukemia treated with desensitization therapy prior to
HLA-haploidentical transplantation with high donor-specific antibodies.
Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775. PubMedAbstract available
TIEN FM, Hou HA CEBPA mutations in acute myeloid leukemia: implications in risk stratification
and treatment.
Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773. PubMedAbstract available
FUJITA H JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute
promyelocytic leukemia (APL).
Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749. PubMed
IRIYAMA N, Iwanaga E, Kimura Y, Watanabe N, et al Changes in chronic myeloid leukemia treatment modalities and outcomes after
introduction of second-generation tyrosine kinase inhibitors as first-line
therapy: a multi-institutional retrospective study by the CML Cooperative Study
Group.
Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758. PubMedAbstract available
TODA Y, Ashizawa M, Murahashi R, Nakashima H, et al Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the
rasburicase era.
Int J Hematol. 2024 Apr 5. doi: 10.1007/s12185-024-03752. PubMedAbstract available
NAKAMURA T, Oya S, Ozawa H, Maehiro Y, et al Correlation of ex vivo and in vivo ammonia production with L-asparaginase
biological activity in adults with lymphoid malignancies.
Int J Hematol. 2024;119:426-431. PubMedAbstract available
March 2024
USUKI K, Miyamoto T, Yamauchi T, Ando K, et al A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in
Japanese patients with high-risk acute myeloid leukemia.
Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733. PubMedAbstract available
XU J, Zong S, Sheng T, Zheng J, et al Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating
mTORC1 pathway-mediated apoptosis and autophagy.
Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03732. PubMedAbstract available
IOANNIDOU M, Avgeros C, Georgiou E, Papadimitriou-Tsantarliotou A, et al Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of
children being treated for acute lymphoblastic leukemia.
Int J Hematol. 2024 Mar 20. doi: 10.1007/s12185-024-03748. PubMedAbstract available
TAKIZAWA J, Suzuki R, Izutsu K, Kiguchi T, et al Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis
of the CLLRSG-01 study.
Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03741. PubMedAbstract available
KAWAKAMI Y, Imamura M, Imai C Isolated salivary gland extramedullary relapse of Philadelphia
chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03756. PubMed
MAEDA Y JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1.
Acute myeloid leukemia (AML).
Int J Hematol. 2024 Mar 14. doi: 10.1007/s12185-024-03730. PubMed
SANO H, Fukushima K, Yano M, Osone S, et al Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a
report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
Int J Hematol. 2024 Mar 9. doi: 10.1007/s12185-024-03745. PubMedAbstract available
XUE S, Sun HP, Huang XB, Chen X, et al Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute
myeloid leukemia.
Int J Hematol. 2024 Mar 5. doi: 10.1007/s12185-024-03729. PubMedAbstract available
AN K, He Y, Tang Y, Gu X, et al Histiocytic sarcoma following CAR T-cell therapy: a case report.
Int J Hematol. 2024;119:338-341. PubMedAbstract available
February 2024
SHIOZAWA Y, Fujita S, Nannya Y, Ogawa S, et al First report of familial mixed phenotype acute leukemia: shared clinical
characteristics, Philadelphia translocation, and germline variants.
Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03724. PubMedAbstract available
CHOED-AMPHAI C, Khorana J, Sathitsamitphong L, Natesirinilkul R, et al Predictive factors for L-asparaginase hypersensitivity in pediatric acute
lymphoblastic leukemia.
Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03725. PubMedAbstract available
YOKOYAMA Y Risk factors and remaining challenges in the treatment of acute promyelocytic
leukemia.
Int J Hematol. 2024 Feb 22. doi: 10.1007/s12185-023-03696. PubMedAbstract available
HISADA Y Dysregulated hemostasis in acute promyelocytic leukemia.
Int J Hematol. 2024 Feb 11. doi: 10.1007/s12185-024-03708. PubMedAbstract available
YANAGI M, Mori M, Honda M, Mitani Y, et al Nelarabine-containing salvage therapy and conditioning regimen in transplants for
pediatric T-cell acute lymphoblastic leukemia and lymphoma.
Int J Hematol. 2024 Feb 1. doi: 10.1007/s12185-023-03701. PubMedAbstract available
MARUYAMA D, Omi A, Nomura F, Touma T, et al Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle
cell lymphoma in Japan: post-marketing surveillance.
Int J Hematol. 2024;119:146-155. PubMedAbstract available
SCHALK E, Pelz AF Auer rods in mature granulocytes in peripheral blood.
Int J Hematol. 2024;119:105-106. PubMed
USUKI K, Ohtake S, Honda S, Matsuda M, et al Real-world data of MDS and CMML in Japan: results of JALSG clinical observational
study-11 (JALSG-CS-11).
Int J Hematol. 2024;119:130-145. PubMedAbstract available
January 2024
UEKI H, Ogawa C, Goto H, Nishi M, et al TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed
childhood acute lymphoblastic leukemia.
Int J Hematol. 2024 Jan 25. doi: 10.1007/s12185-024-03710. PubMedAbstract available
OKAYAMA Y, Harada N, Makuuchi Y, Kuno M, et al Pretransplant hepatomegaly is linked to relapse in patients with leukemia and
myelodysplastic syndrome not in remission.
Int J Hematol. 2024 Jan 22. doi: 10.1007/s12185-023-03707. PubMedAbstract available
KATO K, Takagi S, Takano H, Tsunoda S, et al A case report of a truncated ABL1 mutation in 2 cases with Philadelphia
chromosome-positive B cell precursor acute lymphoblastic leukemia.
Int J Hematol. 2024 Jan 18. doi: 10.1007/s12185-023-03691. PubMedAbstract available
OYAKE M, Hirakuni Y, Hirano N, Suenobu S, et al Abnormal bone marrow T1-weighted MRI images in a pediatric patient with acute
lymphoblastic leukemia without peripheral blasts.
Int J Hematol. 2024 Jan 3. doi: 10.1007/s12185-023-03697. PubMed
USUKI K, Ohtake S, Honda S, Matsuda M, et al Real-world data of AML in Japan: results of JALSG clinical observational study-11
(JALSG-CS-11).
Int J Hematol. 2024;119:24-38. PubMedAbstract available
ITO M, Fukushima N, Fujii T, Numata M, et al Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic
hematopoietic stem cell transplantation.
Int J Hematol. 2024;119:80-87. PubMedAbstract available
December 2023
MAKITA S, Ota S, Mishima Y, Usuki K, et al Japanese phase Ib study of the oral PI3K-delta and -gamma inhibitor duvelisib in patients
with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic
lymphoma.
Int J Hematol. 2023 Dec 27. doi: 10.1007/s12185-023-03689. PubMedAbstract available
ZHAO B, Yin J, Ding L, Luo J, et al SPAG6 regulates cell proliferation and apoptosis via TGF-beta/Smad signal pathway in
adult B-cell acute lymphoblastic leukemia.
Int J Hematol. 2023 Dec 26. doi: 10.1007/s12185-023-03684. PubMedAbstract available
NUKUI J, Tachibana T, Miyazaki T, Tanaka M, et al Clinical significance of total nucleated cell count in bone marrow of patients
with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem
cell transplantation.
Int J Hematol. 2023 Dec 12. doi: 10.1007/s12185-023-03688. PubMedAbstract available
TAKEYASU S, Morita K, Saito S, Toho M, et al Myeloid sarcoma and pathological fracture: a case report and review of
literature.
Int J Hematol. 2023;118:745-750. PubMedAbstract available
MIKI K, Ogasawara R, Sugimura S, Sugita J, et al A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal
perforation.
Int J Hematol. 2023;118:766-771. PubMedAbstract available
November 2023
SHIOMI I, Nakako S, Nakane T, Ogawa Y, et al Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell
precursor acute leukemia.
Int J Hematol. 2023 Nov 27. doi: 10.1007/s12185-023-03678. PubMedAbstract available
SAKAI Y, Ikawa Y, Takenaka M, Noguchi K, et al Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin
infant mimicking aleukemic leukemia cutis.
Int J Hematol. 2023 Nov 21. doi: 10.1007/s12185-023-03675. PubMedAbstract available
October 2023
FUKATSU M, Hamazaki Y, Sato Y, Koyama D, et al A case of cold agglutinin syndrome associated with chronic lymphocytic leukaemia
harbouring mutations in CARD11 and KMT2D.
Int J Hematol. 2023;118:472-476. PubMedAbstract available
UNO S, Motegi Y, Minehata K, Aoki Y, et al Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with
5q deletion: a post-marketing surveillance study.
Int J Hematol. 2023;118:432-442. PubMedAbstract available
September 2023
ZHANG A, Liu L, Zong S, Chang L, et al Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater
than 50 x 10(9)/L.
Int J Hematol. 2023 Sep 21. doi: 10.1007/s12185-023-03665. PubMedAbstract available
HARA R, Machida S, Hashimoto N, Ogiya D, et al Impact of previous anthracycline therapy in patients with acute myeloid leukemia
receiving venetoclax.
Int J Hematol. 2023 Sep 20. doi: 10.1007/s12185-023-03664. PubMedAbstract available